Physician profile
Alan E Solinsky
NPI 1235103904
$13,110.52
in general payments reported to CMS, 2019-2025
30 companies · $3,337 in 2025
The $3,337 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,441 · 2020: $3,471 · 2021: $1,101 · 2022: $646 · 2023: $824 · 2024: $1,289 · 2025: $3,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705 · Consulting Fee: $1,250 · Long Term Medical Supply Or Device Loan: $468 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.93 |
| Consulting Fee | $1,250.00 |
| Long Term Medical Supply Or Device Loan | $468.14 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $2,451.26 | 2019-2021 | |
| Rxsight INC | $1,684.42 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,625.57 | 2019-2021 | |
| Allergan, INC. | $1,505.41 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $1,024.15 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $946.59 | 2019-2025 | Unity, Clareon, Rocklatan |
| Sun Pharmaceutical Industries INC. | $536.15 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $490.58 | 2023-2025 | Vevye, Iheezo |
| Novartis Pharmaceuticals Corporation | $483.22 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $385.09 | 2019-2022 | |
| Abbvie INC. | $377.54 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Oyster Point Pharma, INC. | $267.65 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $227.58 | 2019-2024 | Tecnis Simplicity |
| Tarsus Pharmaceuticals, INC. | $168.79 | 2024-2025 | Xdemvy |
| Omeros Corporation | $143.72 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $123.50 | 2023 | |
| Sight Sciences, INC. | $103.74 | 2019-2021 | |
| Ocular Therapeutix, INC. | $93.99 | 2021-2025 | Dextenza |
| Amgen INC. | $85.95 | 2024-2025 | Tepezza |
| Dompe US, INC. | $63.20 | 2019-2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $60.46 | 2025 | Syfovre |
| Glaukos Corporation | $49.78 | 2024 | Idose |
| Biotissue Holdings INC. | $45.55 | 2022-2024 | |
| Eyevance Pharmaceuticals LLC | $42.83 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $33.42 | 2022 | |
| Coopervision INC. | $25.13 | 2019 | |
| Thea Pharma INC. | $20.93 | 2024 | Iyuzeh |
| Carl Zeiss Meditec Cataract Technology INC. | $19.50 | 2019 | |
| Eyepoint US, INC. | $13.07 | 2019 | |
| Shire North American Group INC | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Solinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.